Syndeio Biosciences

Executive Summary

Syndeio Biosciences is a private, Cambridge-based biotech pioneering a new class of synapse-targeting therapies for neuropsychiatric and cognitive disorders. Founded in 2021, the company leverages its unique synapse pharmacology platform to develop drug candidates with novel mechanisms of action, differentiating it from conventional approaches. Syndeio has advanced a lead candidate into Phase 2 clinical trials, addressing high unmet needs in conditions such as depression and schizophrenia. The company's deep expertise in fundamental synapse biology positions it to potentially deliver breakthrough treatments that modulate synaptic function with improved efficacy and tolerability. While early-stage, Syndeio's innovative platform and Phase 2 assets make it a compelling investment opportunity in the neuropsychiatric space.

Upcoming Catalysts (preview)

• Q3 2026Phase 2a data readout for lead candidate in major depressive disorder60% success
• TBDStrategic partnership or licensing deal for platform technology40% success
• TBDSeries B financing round to support ongoing clinical development70% success